The significance of plasma lysophospholipids in patients with renal failure on hemodialysis

Journal of Nutritional Science and Vitaminology

Volumn 44, Issue 6, 1998, Pages 809-818

  Sasagawa, Takayo ^a   Suzuki, Kazuhiko ^a   Shiota, Tetsuya ^b   Kondo, Tadaaki ^c   Okita, Misako ^a  

^a OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

^b Division of Internal Medicine   (Japan)

^c Shigei Hospital   (Japan)

Author keywords

Dietary fat intake; Hemodialysis; Lysophospholipid; Plasma lipid; Renal failure

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; ICOSAPENTAENOIC ACID; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; PHOSPHATE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; FAT INTAKE; FEMALE; HEMODIALYSIS; HUMAN; LIPID COMPOSITION; MALE; PHOSPHOLIPID BLOOD LEVEL; PHOSPHOLIPID METABOLISM; VITAMIN INTAKE;

EID: 0032453841     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.44.809     Document Type: Article

References (25)

1. Lindner A, Charra B, Sherrard D, Scribner B. 1974. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Eng J Med 290: 697-701.
2. McCosh EJ, Solangi K, Rivers JM, Goodman A. 1975. Hypertriglyceridemia in patients with chronic renal failure. Am J Clin Nutr 28: 1036-1043.
3. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. 1992. The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis 20: 324-335.
4. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. 1997. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 131: 229-236.
5. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthaserthy S, Carew TE, Butler S, Witztum JL, Steinberg D. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095.
6. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri H, Horiuchi S. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 269: 31430-31435.
7. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G. 1994. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45: 876-883.
8. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
9. Okita M, Gaudette DC, Mills GB, Holub BJ. 1997. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 71: 31-34.
10. Yagi K. 1982. Assay for serum lipid peroxide and its clinical significance. In: Lipid Peroxides in Biology and Medicine (Yagi K, ed), p 223-242. Academic Press, New York.
11. McLeod R, Reeve CE, Frohlich J. 1984. Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients receiving maintenance hemodialysis. Kidney Int 25: 683-688.
12. 2 in plasma increases in uremia. Clin Chem 36: 198-200.
13. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. 1995. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 47: 247-253.
14. 2 in signal transduction through protein kinase C. Proc Natl Acad Sci USA 89: 6447-6451.
15. 2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules. Eur J Biochem 217: 723-729.
16. Sakai M, Miyazaki A, Hakamata H, Sato Y, Matsumura T, Kobori S, Shichiri M, Horiuchi S. 1996. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arterioscl Thromb Vasc Biol 16: 600-605.
17. Sasaki Y, Asaoka Y, Nishizuka Y. 1993. Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids. Fed Eur Biochem Soc 320: 47-51.
18. Tokumura A, Harada K, Fukuzawa K, Tsukatani H. 1986. Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma. Biochim Biophys Acta 875: 31-38.
19. Eichholts T, Jalink K, Fahrenfort I, Moolenaar WH. 1993. The bioactive phospholipid lysophosphatidic acid is released from activated platelet. Biochem J 291: 677-680.
20. Cases A, Reverter JC, Escolar G, Sanz C, Sorribes J, Ordinas A. 1997. In vivo evaluation of platelet activation by different cellulosic membranes. Artif Organs 21: 330-334.
21. Nishizawa Y, Shoji T, Kawagishi T, Morii H. 1997. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int 52: S90-S92.
22. Goldstein DJ, Wheeler DC, Salant DJ. 1996. Effects of omega-3 fatty acids on complement-mediated glomerular epithelial cell injury. Kidney Int 50: 1863-1871.
23. Yalçin AS, Yurtkuran M, Dilek K, Kilinç A, Taga Y, Emerk K. 1989. The effect of vitamin E therapy on plasma and erythrocyte lipid peroxidation in chronic hemodialysis patients. Clin Chim Acta 185: 109-112.
24. Toborek M, Wasik T, Drózdz M, Magner-Wróbel K, Kopienczna-Grzebieniak E. 1992. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41: 1229-1232.
25. Anderson JG, Thomas TH, Wilkinson R. 1996. Increased susceptibility to membrane lipid peroxidation in renal failure. Nephron 74: 373-377.